Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Okragly

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Immunology, Immunotherapy : CII|October 27, 2007
Tumor-derived death receptor 6 modulates dendritic cell developmentDavid C DeRosa, Paul J Ryan, Angela Okragly, et al.
Immunotherapy|January 9, 2025
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)Stanley Szefler, Jonathan Corren, Jonathan I Silverberg, et al.
Dermatology and Therapy|July 15, 2025
Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic DermatitisEmma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, et al.
The Journal of Dermatological Treatment|March 12, 2026
Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitisJonathan I Silverberg, Thomas Bieber, Kilian Eyerich, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Immunology, Immunotherapy : CII|October 27, 2007
Tumor-derived death receptor 6 modulates dendritic cell developmentDavid C DeRosa, Paul J Ryan, Angela Okragly, et al.
Immunotherapy|January 9, 2025
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)Stanley Szefler, Jonathan Corren, Jonathan I Silverberg, et al.
Dermatology and Therapy|July 15, 2025
Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic DermatitisEmma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, et al.
The Journal of Dermatological Treatment|March 12, 2026
Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitisJonathan I Silverberg, Thomas Bieber, Kilian Eyerich, et al.
Pageof 1